ClinicalTrials.gg
Not yet recruitingNCT07420010Updated Feb 19, 2026

An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.

An Early Phase 1 interventional study of KT032(anti-MSLN chimeric antigen receptor autologous T cell injection) in Ovarian Cancer, Mesothelioma and Colon Cancer, sponsored by Weijia Fang, MD. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Weijia Fang, MD · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.

Read the detailed description

This is a single-arm, single-center, open-label, dose-escalation and expansion study to investigate the safety and tolerability, pharmacokinetics, and preliminary efficacy of the investigational product administered via intraperitoneal injection in adult patients with advanced solid tumors.

Dose-Escalation Phase: After providing informed consent, subjects will be screened for eligibility based on inclusion/exclusion criteria. Eligible subjects will receive KT032 treatment. Dose escalation will follow the "3+3" principle across three dose cohorts: 1.0×10⁶, 2.0×10⁶, and 3.0×10⁶ CAR-T cells/kg (for the highest dose cohort, dosing will be calculated based on 70 kg for subjects weighing >70 kg). Given the special nature of the cellular product, a ±20% variance in the actual administered dose is permitted for each cohort. This phase plans to enroll 12-18 subjects with single-dose administration.

Dose-Expansion Phase: Based on data from the dose-escalation phase, one optimal dose cohort will be selected to expand with 6 additional subjects. The specific expansion study plan and sample size will be determined according to preliminary safety, PK, and efficacy data obtained during the dose-escalation phase.

02

Conditions studied

  • Ovarian Cancer
  • Mesothelioma
  • Colon Cancer

Keywords

  • CAR-T
  • Mesothelin-positive Advanced Solid Tumors
03

In context

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

This study's planned enrollment of 24 is below the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

Weijia Fang, MD is the lead sponsor of 8 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 75 years (inclusive), any gender;
  2. Histopathologically confirmed diagnosis of advanced solid tumors (including but not limited to ovarian cancer, mesothelioma, colon cancer, etc.), with peritoneal or intraperitoneal as the primary disease manifestation;
  3. Progression or intolerance to prior systemic standard-of-care treatment according to guidelines (systemic therapy includes but is not limited to systemic chemotherapy, molecular targeted therapy, etc.), and unsuitable for surgery or local treatment (including ablation therapy, interventional therapy, and radiotherapy); specifically: Ovarian cancer: Recurrence during or within 6 months after or later platinum-based chemotherapy; Mesothelioma: Failure of, intolerance to, or ineligibility for at least first-line therapy; Colon cancer: Failure of, intolerance to, or ineligibility for at least third-line therapy;

    1. Ovarian cancer: Progression, intolerance, or ineligibility after second-line standard therapy including carboplatin ± paclitaxel/albumin-bound paclitaxel/docetaxel/pegylated liposomal doxorubicin;
    2. Advanced colon cancer: Progression, intolerance, or ineligibility after third-line standard therapy including cetuximab ± irinotecan/regorafenib/fruquintinib/trifluridine/tipiracil;
    3. Mesothelioma: Progression, intolerance, or ineligibility after first-line standard therapy with pemetrexed combined with cisplatin/carboplatin;
  4. Presence of at least one per 1.1 criteria;
  5. MSLN expression positivity in tumor tissue detected by immunohistochemistry (IHC), defined as IHC ≥2+ (i.e., ≥26% positive tumor cells stained); subjects must undergo fresh tumor tissue ; if biopsy is not feasible, at least 5 archived tumor tissue slides collected within one year must be provided (if multiple tumor tissue collections exist, the most recent sample is preferred);
  6. performance status 0-1 (see Appendix 1) and estimated >12 weeks;
  7. Adequate organ function with all following laboratory results prior to enrollment:

    Hematology: (ANC) ≥1.5×10⁹/L (growth factor support allowed, but must not have received within 7 days prior to laboratory testing); Absolute lymphocyte count (ALC) ≥0.7×10⁹/L; ≥100×10⁹/L (no transfusion support within 7 days prior to laboratory testing); ≥90 g/L (no RBC transfusion within 7 days prior to laboratory testing; recombinant human erythropoietin allowed); Hepatic function: (ALT) and aspartate aminotransferase (AST) ≤2.5× (ULN); Total serum ≤2×ULN; ALT and AST may be extended to ≤5×ULN if abnormalities are determined by the investigator to be due to disease (e.g., hepatic metastases or biliary obstruction) or Gilbert's syndrome; Renal function: (CrCl) ≥50 mL/min calculated by Cockcroft-Gault formula; Coagulation function: Fibrinogen ≥1.0 g/L; ≤1.5×ULN; Prothrombin time (PT) ≤1.5×ULN; Oxygen saturation >91% (on room air); (LVEF) ≥50%;

  8. Recovery from all toxicities related to prior treatment to acceptable baseline status, or recovery to normal or Grade 1 per 5.0, as determined by the investigator; except for toxicities not expected to increase safety risk of subsequent product infusion, such as alopecia, vitiligo, etc.;
  9. Agreement by subjects and their partners to use effective methods (excluding rhythm method) from the time of signature until one year after CAR-T cell infusion;
  10. Written informed consent on IRB/IEC-approved consent form obtained personally from the subject prior to initiation of any screening procedures.

Exclusion criteria

Exclusion Criteria:

  1. Other within 5 years prior to screening, except adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, or ductal carcinoma in situ of the breast after radical surgery;
  2. surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive with peripheral blood hepatitis B virus (HBV) DNA titer above the lower limit of detection of the quantitative assay at the study site; virus (HCV) antibody positive with peripheral blood HCV RNA above the lower limit of detection of the quantitative assay at the study site; (HIV) antibody positive; Positive syphilis test;
  3. Patients with central nervous system and/or other unstable central nervous system diseases (hemorrhage, active infarction, infection, etc.);
  4. Receipt of within 4 weeks prior to cell injection;
  5. History of to prior immunotherapy, allergy or intolerance to fludarabine, cyclophosphamide, albumin-bound paclitaxel conditioning regimen drugs, or tocilizumab, or allergy to components of the product formulation, or history of other severe allergic reactions;
  6. Poorly controlled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg) or (e.g., active) cardiovascular disease, such as cerebrovascular accident (within 6 months prior to main signature), myocardial infarction (within 6 months prior to main informed consent signature), unstable angina, (NYHA) Class II or greater congestive heart failure, or serious arrhythmia not controlled by medication or potentially affecting study treatment; Clinically significant abnormalities on in 3 consecutive readings (at least 5 minutes apart each) or mean ≥450 ms;
  7. Other severe organic diseases or psychiatric disorders;
  8. , interstitial lung disease, or clinically significant abnormal pulmonary function test results;
  9. diseases: History of autoimmune disease deemed unsuitable for this study by the investigator, such as systemic lupus erythematosus, vasculitis, infiltrative lung disease (subjects with vitiligo are excluded from this exclusion criterion);
  10. Systemic (topical use allowed), hydroxyurea, immunomodulatory agents (e.g., α or γ interferon, GM-CSF, mTOR inhibitors, cyclosporine, thymosin, etc.) within 2 weeks prior to screening or planned use during the study (if long-term use exists);
  11. Chemotherapy within 2 weeks prior to cell injection, immunotherapy within 4 weeks, radiotherapy within 12 weeks prior to infusion, or other antineoplastic agents with insufficient of less than 5 half-lives;
  12. Pregnant or lactating women, and female subjects planning pregnancy within 1 year after cell infusion;
  13. Subjects with any concurrent medical condition or disease that the investigator determines may interfere with study conduct;
  14. Receipt of other cellular or gene therapy products within 3 months prior to cell injection, or patients deemed unsuitable for enrollment by the investigator;
  15. Patients whom the investigator determines will have difficulty completing all study visits or procedures (including follow-up period), or with insufficient compliance; or patients deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    KT032:1.0×10⁶ CAR-T cells/kg

    Biological: KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)

  • Experimental
    KT032:2.0×10⁶ CAR-T cells/kg

    Biological: KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)

  • Experimental
    KT032:3.0×10⁶ CAR-T cells/kg

    Biological: KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)

Interventions

  • BiologicalKT032(anti-MSLN chimeric antigen receptor autologous T cell injection)

    Lymphodepletion conditioning is required prior to administration of anti-MSLN chimeric antigen receptor autologous T cell injection (KT032). KT032 is administered via intraperitoneal injection (10-30 ml cell injection solution by intraperitoneal bolus), 1 bag per dose, for a total of 1 dose. The investigational product dose will be determined based on the subject's body weight and the number of viable CAR-positive T cells. Dosing according to the pre-specified dose levels: 1.0×10⁶ CAR-T cells/kg, 2.0×10⁶ CAR-T cells/kg, and 3.0×10⁶ CAR-T cells/kg (for the highest dose cohort, if body weight exceeds 70 kg, dose calculation will be based on 70 kg). Given the special nature of cell products, an actual dosing variation of ±20% is permitted for each dose cohort.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity(DLT)

    Safety

    Time frame: 28 days

  2. Maximal Tolerable Dose(MTD)

    tolerability evaluation

    Time frame: 28 days

  3. Adverse Event(AE)

    Incidence rate

    Time frame: Disease progression, withdrawal from the study, death, or 2 years following cell administration, whichever occurs first

  4. Serious Adverse Event(SAE)

    Incidence rate

    Time frame: Disease progression, withdrawal from the study, death, or 2 years following cell administration, whichever occurs first

  5. Adverse Event of Special Interest ( AESI)

    Incidence rate

    Time frame: Disease progression, withdrawal from the study, death, or 2 years following cell administration, whichever occurs first

Secondary outcomes

  1. PK

    CAR-T cells in peripheral blood were analyzed by flow cytometry, and CAR-T copy numbers in peripheral blood were quantified by quantitative PCR (qPCR); patients were followed until CAR-T cells and CAR-T copy numbers in peripheral blood were below the lower limit of quantification (LLOQ) in two consecutive assessments.

    Time frame: 2 years

  2. Antitumor efficacy-Objective response rate (ORR)

    Proportion of patients with Best Overall Response(BOR) of PR or CR

    Time frame: 2 years

  3. Disease Control Rate (DCR)

    Proportion of patients with BOR of PR, CR, or SD

    Time frame: 2 years

  4. Duration of Response (DOR)

    Time interval from first documented CR or PR to first documented PD or death from any cause;

    Time frame: 2 years

  5. Progression-Free Survival (PFS)

    Time from initiation of KT032 cell therapy to first disease progression or death from any cause, whichever occurs first

    Time frame: 2 years

  6. Overall Survival (OS)

    Time from initiation of KT032 cell therapy to death (from any cause)

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2028, 33 months later.

Of 172 non-industry phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's planned 33 months is below that.

Counting every sponsor, half of 382 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartEst.
Mar 15, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07420010
Lead sponsor
Weijia Fang, MD
Responsible party
Weijia Fang, MD (Director,Principal Investigator, Zhejiang University) — Sponsor-investigator
First posted
Feb 19, 2026
Start date
Mar 15, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Feb 19, 2026

Study contacts

Weijia Fang, MD
Contact
weijiafang@zju.edu.cn
86-0571-87237587
Wenyu Wang
Contact
wywang0815@163.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion